Best in Class
C. difficile
Containment*

*Class defined as market leading stool/fecal management systems. Non-Clinical data, may not correlate to clinical outcomes.

The Evolution of
Fecal Management
Fecal Management of the Past

Ineffective

Ineffective¹
FECAL MANAGEMENT TODAY

Flexi-Seal™ Signal™
FECAL MANAGEMENT SYSTEM

DIGNISHIELD®
STOOL MANAGEMENT SYSTEM

STANDARD OF CARE FOR
PROTECTING THE SKIN¹
HOSPITAL ACQUIRED CONDITION REDUCTION PROGRAM

FISCAL YEAR 2016

- **CLABSI** (Central Line-Associated Bloodstream Infection)
- **CAUTI** (Catheter-Associated Urinary Tract Infection)
- **SSI** (Surgical Site Infection)

**75%**

FISCAL YEAR 2017

- **C. diff** (Clostridium difficile)
- **MRSA** (Methicillin-resistant Staphylococcus aureus)
- **SSI** (Surgical Site Infection)
- **CLABSI** (Central Line-Associated Bloodstream Infection)
- **CAUTI** (Catheter-Associated Urinary Tract Infection)

**85%**

*For Applicable Acute Care Hospitals*

*HAC Score Domain 2 Weighting

+ SSI measures include colon and abdominal hysterectomy only
Closed System Design demonstrated to be effective in a bench study simulating clinical use

CONTAINING *C. difficile*
REDUCE THE RISK OF MISCONNECTIONS

The ENFit™ Connector

- ENFit™ compatible irrigation port allows for the use of ENFit™ syringes
- Delivery of medication through the rectal route
- Instill fluid to check patency or to irrigate the rectum
- All while reducing the risk of device misconnections
ODOR CONTROL

In-Vivo Resting Cuff Pressure vs. Fill Volume

- Low pressure, anatomical cuff design
- In simulated bench tests the BARD® DIGNI SHIELD® SMS offers an average of 69% less resting pressure than other commercially available fecal management devices

Hydrogen Sulfide Detected Over 8 hrs.

76% less permeable to odor causing compounds*

Average retention cuff pressure for subjects in three different positions and at three different elevation angles.

*Bench data on file, may not correlate to clinical use
## DIGNISHIELD® STOOL MANAGEMENT SYSTEM

For more information about the DIGNISHIELD® Stool Management System and other BARD® products, please contact your sales representative or call 800.526.4455.

<table>
<thead>
<tr>
<th>Product Code</th>
<th>DIGNISHIELD® Stool Management System</th>
<th>Case Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>DigniShield® SMS Collection Bags</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>SMS002</td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product Code</th>
<th>DIGNISHIELD® Stool Management System with the ENFit™ Connector</th>
<th>Case Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>DigniShield® SMS Collection Bags</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>ENSMS002</td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>

### Indications:
The BARD® DIGNISHIELD® Stool Management System (SMS) with odor barrier properties is intended for fecal management by diverting and collecting liquid or semi-liquid stool in bedridden patients and to provide access for the administration of medications.

### Contraindications:
The device should not be used for more than 29 consecutive days, on patients with certain medical conditions including rectal or anal abnormalities, or on patients who have had lower large bowel or rectal surgery within the last year. Do not use on patients with indwelling rectal or anal device, delivery mechanisms, or enemas in place.

### Warnings and Adverse Events:
There is a potential risk of misconnections with connectors from other healthcare applications. As with the use of any rectal device, adverse events can occur including: leakage of stool, loss of anal sphincter muscle tone, pressure necrosis, infection, bowel obstruction, and perforation of the bowel. Changes to the patient including: rectal bleeding indicating possible pressure necrosis, abdominal distention, cuff migration, and rectal pain should be investigated.

Please consult package insert for more detailed safety information and instructions for use.

---